Weekly Digests

2021

October

Chemotherapy and checkpoint inhibition differentially impact immune dynamics

October 20, 2021

While the effects of immune checkpoint blockade on the tumor microenvironment (TME) are widely investigated, the combined effect of chemotherapy and checkpoint blockade is less clear. Further, although the Impassion130 trial in advanced triple-negative breast cancer (TNBC) combining nab-paclitaxel with anti-PD-L1 therapy led to clear patient benefits and product approval, a similar trial...

When neoantigen expression is low, the T cells won’t go

October 13, 2021

In the setting of colorectal cancer (CRC), mismatch repair (MMR)-deficient or microsatellite instability (MSI)-high disease tends to have higher tumor mutation burdens (TMB) and better responses to immunotherapy than MMR-proficient and microsatellite stable (MSS) disease. However, MSS CRC still has a mutation burden that is comparable to other cancers that respond to immunotherapy...

T cells with an identity crisis: gaining NK characteristics after CMV infection

October 6, 2021

Human cytomegalovirus (HCMV) infection can have long-term immune effects, and NK and T cells both play roles in keeping HCMV latent. Based on the knowledge that CD8+ T cells can display NK cell-like properties, and that these cells can have a beneficial presence in individuals infected with particular intracellular pathogens causing tuberculosis or...

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.